The developed electrochemical immunosensor provides a highly sensitive method for detecting IL-37, with potential applications in clinical diabetes diagnosis.
Hypothesis-generating for IL-37 diabetes diagnostics; human validation required before clinical adoption.
Interleukin-37 (IL-37) has been sensitively detected by the electrochemical immunosensors owing to the dual amplification of AuNP-PDA (gold nanoparticles and Polydopamine). PDA was employed as an immobilization biomolecules not only to construct a sensor platform but also to label signal. The amplification of the sensitivity can be achieved by the employment of particular AuNP-PDA platform and AuNP-PDA@graphene modified by HRP-Ab2 (horseradish peroxidase and antibody). The response of IL-37 was evaluated by the determination of amperometry, and the linear range is starting from 4 pg/mL to 800 pg/mL and the detection limit was very low (0.8 pg/mL). The performance of immunosensors for detecting IL-37 in human serum was compared with assays of standard ELISA. Furthermore, the diagnosis of clinic diabetes would be potentially achieved by this well-defined immunosensor.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: